Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 42, n° 3
pages 496-500 (mars 2000)
Doi : 10.1016/S0190-9622(00)90226-3
A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas

Reuven Bergman, MDa-c, Halim Azzam, MDa, Eli Sprecher, MD, PhDa, Lena Manov, MScc, Mariana Munichor, MDb, Rachel Friedman-Birnbaum, MDa, Offer Ben-Itzhak, MDb
Haifa, Israel 
From the Department of Dermatology,a the Department of Pathology,b and the Dermatopathology Unit,c Rambam Medical Center, and the Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 


Background: The histopathologic differential diagnosis of Spitz nevus (SN) from malignant melanoma (MM) may be difficult. Objective: We attempted to elucidate the pattern of expression of a newly recognized melanocyte-specific melanosomal protein MART-1 in routinely processed specimens of SNs, MMs, and ordinary melanocytic nevi (MNs) and to see whether it can help to differentiate between them. Methods: Twenty SN, 22 MM, and 27 ordinary MN were immunostained with anti-MART-1 monoclonal antibody (clone A103). Results: All SNs, MNs, and MMs demonstrated cytoplasmic staining for MART-1 in some of their tumor cells, of which 17 of 20 (85%) and 24 of 27 (89%) of SN and MN, respectively, demonstrated positive stainings in more than half of their tumor cells, as compared with only 10 of 22 (45%) of the MM (P < .05). The majority of lesions in all 3 types of tumors showed a homogeneous mode of staining, although MM tended to show a more heterogeneous pattern. A consistent pattern of stratification of staining with progressive descent into the dermis was not demonstrated in these tumors. Conclusion: MART-1 does not differentiate between SN, MM, and ordinary MN in a consistent pattern, but it may be used as a marker for these tumors. (J Am Acad Dermatol 2000;42:496-500.)

The full text of this article is available in PDF format.

 Reprint requests: Reuven Bergman, MD, Department of Dermatology, Rambam Medical Center, Haifa 31096, Israel.

© 2000  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@